This could be second highest year for biotech venture capital

Dollar SignsLast year was a record 12-month period for biotech venture capital, and this one could come in just behind 2015, making it the second highest ever. Read more here.

Tom Ballard

By Tom Ballard, Chief Alliance Officer,
Pershing Yoakley & Associates. P.C.

eNews & Updates

Sign up to receive posts via email.

Connect With Us

Upcoming Events

Links to Partners